Drug intelligence / Profile preview

AD-2284

Development stage: Unknown
Lead developer: Addpharma
Modality: Small Molecules
Administration: Oral

Overview

AD-2284 is an investigational drug being evaluated in clinical trials for the treatment of primary hypercholesterolaemia. It is currently being compared to another investigational agent, AD-228B, in a phase 1 crossover study designed to assess pharmacokinetic characteristics and safety profiles in healthy subjects. The trial is sponsored by Addpharma Inc., and both drugs are administered orally as tablets. The specific mechanism of action, chemical structure, or detailed pharmacological class of AD-2284 has not been disclosed in publicly available sources[2][3][9].

Beyond the preview

Go deeper on AD-2284.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD-2284.

Explore the full profile